APTX Aptinyx Inc.

3.01
-0.25  -8%
Previous Close 3.26
Open 3.23
Price To Book 0.81
Market Cap 101,328,851
Shares 33,664,070
Volume 47,314
Short Ratio
Av. Daily Volume 122,112
Stock charts supplied by TradingView

NewsSee all news

  1. Aptinyx to Present Preclinical Data on Three Clinical-Stage NMDA Receptor Modulators at the 49th Annual Meeting of the Society for Neuroscience

    EVANSTON, Ill., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

  2. Aptinyx to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    EVANSTON, Ill., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

  3. Three Recent Preclinical Publications Highlight NMDA Receptor Activation Facilitated by Aptinyx's NYX-2925

    EVANSTON, Ill., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

  4. INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati

  5. Former Principal Deputy Commissioner of FDA, Dr. Rachel Sherman, Joins Aptinyx Board of Directors

    EVANSTON, Ill., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

First‐in‐patient Phase 2 data 2H 2021.
NYX-458
Parkinson’s Disease Cognitive Impairment (healthy volunteers)
Phase 2 data 1H 2021.
NYX-2925
Fibromyalgia
Phase 2 data released January 16, 2019 - primary endpoint not met. Additional Phase 2 trial to be initiated 2H 2019 with data due 4Q 2020 / 1Q 2021.
NYX-2925
Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Phase 2 data due 2H 2020.
NYX-783
Post-traumatic stress disorder (PTSD)

Latest News

  1. Aptinyx to Present Preclinical Data on Three Clinical-Stage NMDA Receptor Modulators at the 49th Annual Meeting of the Society for Neuroscience

    EVANSTON, Ill., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

  2. Aptinyx to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    EVANSTON, Ill., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

  3. Three Recent Preclinical Publications Highlight NMDA Receptor Activation Facilitated by Aptinyx's NYX-2925

    EVANSTON, Ill., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

  4. INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati

  5. Former Principal Deputy Commissioner of FDA, Dr. Rachel Sherman, Joins Aptinyx Board of Directors

    EVANSTON, Ill., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,